ECSP19045511A - Composiciones y métodos para inhibir la acción de la arginasa - Google Patents

Composiciones y métodos para inhibir la acción de la arginasa

Info

Publication number
ECSP19045511A
ECSP19045511A ECSENADI201945511A ECDI201945511A ECSP19045511A EC SP19045511 A ECSP19045511 A EC SP19045511A EC SENADI201945511 A ECSENADI201945511 A EC SENADI201945511A EC DI201945511 A ECDI201945511 A EC DI201945511A EC SP19045511 A ECSP19045511 A EC SP19045511A
Authority
EC
Ecuador
Prior art keywords
arginase
methods
compositions
inhibiting
action
Prior art date
Application number
ECSENADI201945511A
Other languages
English (en)
Inventor
Francesco Parlati
Matthew Gross
Lijing Chen
Jim Li
Roland Billedeau
Zandt Michael Van
Lene Petersen
Darren Whitehouse
Eric Sjogren
Timothy Stanton
Gunnar Jagdmann
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19045511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of ECSP19045511A publication Critical patent/ECSP19045511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción consiste en una clase novedosa de compuestos que muestran actividad inhibitoria de la arginasa, y composiciones farmaceúticas que incluyen los compuestos de la descripción. En la presente también se ofrecen los métodos de tratamiento contra el cáncer con los inhibidores de la arginasa de la descripción.
ECSENADI201945511A 2016-12-22 2019-06-26 Composiciones y métodos para inhibir la acción de la arginasa ECSP19045511A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28
PCT/US2017/068307 WO2018119440A1 (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
ECSP19045511A true ECSP19045511A (es) 2019-10-31

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201945511A ECSP19045511A (es) 2016-12-22 2019-06-26 Composiciones y métodos para inhibir la acción de la arginasa

Country Status (34)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3842442B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN114989205A (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3842442T3 (es)
EC (1) ECSP19045511A (es)
ES (2) ES2881395T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX378460B (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911240PA (es)
SI (1) SI3559009T1 (es)
SM (1) SMT202100573T1 (es)
TW (1) TWI818902B (es)
UA (1) UA124711C2 (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
EP3842442B1 (en) * 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
KR102668252B1 (ko) 2018-08-22 2024-05-21 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PH12021551902A1 (en) 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022016195A1 (en) * 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4460585A4 (en) * 2022-01-07 2026-03-04 Univ Columbia Inhibition of kynurene synthesis and/or signaling for the treatment of leukemia and myelodysplasia
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
KR20250169642A (ko) 2023-03-13 2025-12-03 인사이트 코포레이션 키나제 억제제로서의 이환식 우레아
WO2026076207A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP2287191B1 (en) 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036652A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
US20080119491A1 (en) 2006-09-19 2008-05-22 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
MX2009005370A (es) 2006-11-21 2009-10-16 Univ Groningen Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica.
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
WO2009008415A1 (ja) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. 二重反転式軸流送風機
EP2214660A2 (en) 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
CN102083429B (zh) 2008-04-24 2014-05-28 新联基因公司 Ido抑制剂
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
ES2524266T3 (es) 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
TR201910726T4 (tr) 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2793657A1 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
AU2011242562B2 (en) 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
PL3412676T3 (pl) * 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
AU2011295440B2 (en) 2010-08-27 2015-06-11 Merck Patent Gmbh Triazolopyrazine derivatives
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
NO2694640T3 (es) 2011-04-15 2018-03-17
US8809378B2 (en) 2011-06-19 2014-08-19 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
EA201490052A1 (ru) 2011-06-23 2014-04-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2012300275A1 (en) 2011-08-30 2014-03-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2014120166A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP3351541A1 (en) 2011-12-11 2018-07-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2013110309A1 (en) 2012-01-28 2013-08-01 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
JP6059260B2 (ja) 2012-02-21 2017-01-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 環状ジアミノピリジン誘導体
JP6049768B2 (ja) 2012-03-07 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ トリアゾロピラジン誘導体
IN2014DN09678A (es) 2012-04-18 2015-07-31 Mars Inc
WO2014023385A1 (en) 2012-08-07 2014-02-13 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
WO2014043376A1 (en) 2012-09-12 2014-03-20 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
EP2914263A4 (en) 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
ES2636936T3 (es) 2013-03-05 2017-10-10 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
EA201591610A1 (ru) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. Ингибиторы кинуренинового пути
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
CN105324362B (zh) 2013-03-15 2017-05-24 百时美施贵宝公司 Ido抑制剂
MX2015011374A (es) 2013-03-15 2016-01-15 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (ido).
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
HK1223093A1 (zh) 2013-05-28 2017-07-21 Viamet Pharmaceuticals (NC), Inc. 杀真菌组合物
JP2016528197A (ja) 2013-07-01 2016-09-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
CA2917964A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors
US10821178B2 (en) 2013-07-29 2020-11-03 Board Of Regents Of The University Of Nebraska Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
JP6371851B2 (ja) 2013-08-27 2018-08-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
EA201991770A1 (ru) 2013-11-08 2019-12-30 Инсайт Холдингс Корпорейшн Способ синтеза ингибитора индоламин-2,3-диоксигеназы
SG10201806297VA (en) 2014-02-04 2018-08-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
KR20160145640A (ko) 2014-04-15 2016-12-20 다우 아그로사이언시즈 엘엘씨 살진균제로서의 금속효소 억제제 화합물
CN106231901A (zh) 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
AU2015311826B2 (en) 2014-09-05 2019-05-23 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (IDO) antagonists for the treatment of cancer
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
EP3270907A1 (en) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
JP2018519245A (ja) 2015-04-03 2018-07-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
WO2016181349A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3842442B1 (en) * 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
EP3559009B1 (en) 2021-04-07
MX2020013649A (es) 2021-02-26
AU2017382405A1 (en) 2019-06-27
MX2019007471A (es) 2019-11-05
EP3842442A1 (en) 2021-06-30
US10597411B2 (en) 2020-03-24
CY1124483T1 (el) 2022-07-22
HUE054272T2 (hu) 2021-09-28
CN110382508B (zh) 2022-08-02
US11021495B2 (en) 2021-06-01
JP7018949B2 (ja) 2022-02-14
TWI818902B (zh) 2023-10-21
JP2022066199A (ja) 2022-04-28
EP3559009A1 (en) 2019-10-30
US20210261573A1 (en) 2021-08-26
BR112019012589A2 (pt) 2019-11-19
DK3559009T3 (da) 2021-05-03
SI3559009T1 (sl) 2021-08-31
SG10201911240PA (en) 2020-02-27
JP2020514271A (ja) 2020-05-21
TW201828948A (zh) 2018-08-16
DK3842442T3 (da) 2024-02-05
KR20190119579A (ko) 2019-10-22
CN110382508A (zh) 2019-10-25
KR102579849B1 (ko) 2023-09-18
WO2018119440A1 (en) 2018-06-28
PT3559009T (pt) 2021-05-04
ES2970715T3 (es) 2024-05-30
US20180222926A1 (en) 2018-08-09
MY197478A (en) 2023-06-19
BR112019012589B1 (pt) 2022-11-29
RS61996B1 (sr) 2021-07-30
US10287303B2 (en) 2019-05-14
US20200339607A1 (en) 2020-10-29
CN114989205A (zh) 2022-09-02
CR20190339A (es) 2020-01-10
CA3046987A1 (en) 2018-06-28
SG10201911243WA (en) 2020-02-27
AU2017382405B2 (en) 2021-12-16
IL267532B (en) 2022-06-01
LT3559009T (lt) 2021-06-25
MX378460B (es) 2025-03-10
PE20191541A1 (es) 2019-10-23
SMT202100573T1 (it) 2021-11-12
ES2881395T3 (es) 2021-11-29
MD3559009T2 (ro) 2021-07-31
AU2022201072A1 (en) 2022-03-10
US12054501B2 (en) 2024-08-06
PH12019501396A1 (en) 2019-12-02
UA124711C2 (uk) 2021-11-03
US20190330244A1 (en) 2019-10-31
IL267532A (en) 2019-08-29
HRP20210848T1 (hr) 2021-07-09
CO2019007839A2 (es) 2019-10-21
PL3559009T3 (pl) 2021-10-25
CL2019001711A1 (es) 2020-01-17
NZ754364A (en) 2023-04-28
EP3842442B1 (en) 2023-11-01
IL292677A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MX2018013593A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
JOP20180038A1 (ar) مثبطات pd-1/pd-l1